[Experiences with Volm's short-term tumor test in the primary treatment of ovarian carcinoma].
It is possible to examine about 95% of tumors using the short-term tumor test from Volm et al. The test results are available within one day. In 89 cases of ovarian tumor stages III and IV, the clinical progress using different chemotherapies could be compared with the results of the uridine-adriamycin-test. In the uridine-adriamycin-test, 82% of the cases with sensitive tumors showed either a remission or at least no change. Resistant tumors were, however, in 56% of cases progressive. Whilst combination largely of proliferation-inhibiting cytostatic drugs such as CF- or CAP-therapy showed a good relationship between the behavior of the tumors in vitro and their response to the cytostatic therapy a similar relationship under CP-therapy with a high cisplatin dosage, could not yet be proved, although until now in only a small number of cases. In vitro sensitive ovarian carcinomas stage III with the histological grade II or III, have a better prognosis under chemotherapy than resistant carcinomas. The importance attached to the short-term tumor test from Volm in the cytostatic therapy of ovarian carcinomas, must be similarly assessed as that of steroid receptors to the endocrine therapy of breast cancer.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002277:Carcinoma / Q000188:drug therapy*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D004351:Drug Resistance; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011379:Prognosis; D013936:Thymidine / Q000378:metabolism; D014529:Uridine / Q000378:metabolism
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil; C011272:perfosfamide; D013936:Thymidine; D014529:Uridine
Erfahrungen mit dem Kurzzeit-Tumortest nach Volm bei der Primärtherapie des Ovarialkarzinoms.